Bristol’s Opdivo Joins Keytruda, Imfinzi In Perioperative NSCLC Treatment Space

 
• By Joseph Haas
  
Bristol Myers Squibb office building in Brisbane, CA
BMS's Opdivo gets approval for perioperative therapy in resectable NSCLC • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from New Products

More from Scrip